Vineti Completes $33.5M in Series B

The funding will also support Vinetis further expansion in Europe and Asia-Pacific, providing a global solution to a critical personalized medicine barrier. "Vineti is humbled to be working with the leading scientific, clinical trial, and commercial teams in personalized medicine. "Ultimately, this successful transformation of legacy infrastructure means radically improved efficiency, transparency, and patient confidence in personalized therapies." The Vineti platform is available directly from Vineti. The company is growing rapidly, and the Vineti platform is now in use world-wide.